Crispr Therapeutics (CRSP) shares rebounded on Monday amid renewed takeover speculation, following fresh chatter that a prospective bidder may be advancing a potential acquisition effort.

Traders cited a Betaville “uncooked” alert indicating that the unidentified buyer has now hired an adviser to move the process forward.

Reports Suggest Potential Bidder Has Engaged Skadden

According to people familiar with the matter, there is talk that the potential acquirer has retained Skadden, Arps, Slate, Meagher & Flom, a major global law firm known for handling large-scale M&A transactions.

Key Details From Market Chatter

Adviser reportedly engaged to advance a takeover bid
Rumors circulated from Betaville’s “uncooked” alert system
Signals possible escalation from early-stage exploration to structured evaluation

Previous Rumors Pointed to a Large U.S. Biopharma

Last month, Betaville reported that a U.S. biopharma company valued between $100B and $200B may be evaluating a bid for Crispr Therapeutics.

Possibly Interested Categories

(Though the report did not name companies, this market-cap range typically includes major pharma players.)

Large-cap gene therapy and biotech firms
M&A-active biopharma companies
Strategic buyers seeking gene-editing technology

Why Crispr Therapeutics Is a Takeover Target

Crispr Therapeutics is a leader in gene-editing technologies, including CRISPR/Cas9, and recently achieved multiple regulatory milestones with its treatment portfolio.

Attractive Assets

Cutting-edge gene-editing intellectual property
Commercial progress in hemoglobinopathies
Strong therapeutic pipeline
Strategic value for pharma entering genetic medicine